歌禮製藥(01672.HK)披露治療慢性乙肝藥物臨床試驗結果
歌禮製藥-B(01672.HK)公布,已在歐洲肝臟研究協會(EASL) 2022年國際肝臟大會(ILC 2022)上口頭報告了皮下注射PD-L1抗體ASC22(恩沃利單抗)治療慢性乙型肝炎患者IIb期臨床試驗的最新結果。
IIb期臨床試驗數據進一步顯示ASC22+NAs的治療方案在功能性治癒慢乙肝方面的潛力,治療期間ALT一過性反跳可作為預測或監測患者對慢乙肝治療反應的指標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.